Three projects from Ascenion’s partner institute have been awarded translational funding. Two of the teams hope to develop novel antivirals, the third is working to create a new diagnostic platform.

The company will use the proceeds to advance its groundbreaking optoacoustic imaging technology into clinical practice. If successful, it would provide a superior, non-invasive alternative to established diagnostic procedures in many diseases.

We have all seen the digital health trend approaching – but it has nevertheless surprised us with its speed and force. Here our summary of last year’s highlights, start-up projects and key figures, in the field of digital health and beyond.

The German Federal Ministry of Education and Research (BMBF) is providing EUR 6.5 million in funding for 10 selected research projects targeting long-term symptoms of COVID-19. Ascenion’s partner institutes are making significant contributions to three of these projects.

Ascenion welcomes two new colleagues: Rebecca Engels is coordinating Ascenion’s activities in the GO-Bio initial programme from our Munich office, and Arturo Robertazzi supports our Berlin team as technology manager.

Be part of Munich’s vibrant bioentrepreneurial ecosystem and sign up now! In 2021, the event will be delivered in a fully virtual format.

25 August 2021, Munich – Cardior Pharmaceuticals has closed a Series B financing round totalling EUR 64 million (USD 76 million). The round was led by…

The method, SARSeq (Saliva Analysis by RNA sequencing), enables highly sensitive, massively-parallel and cost-effective testing for SARS-CoV-2. Ascenion has supported its patent protection and licencing for commercial use in China.

The start-up has also been certified as a medical device manufacturer in the EU. Its x-c-bleeding product uses AI-based software to predict the risk of post-operative bleeding in patients in intensive care units.

The start-up has dosed the first participant in a Phase I study with its lead candidate HRX-0215. The small molecule holds strong potential to restore the liver’s natural capacity to regenerate itself, both in acute and chronic liver disease.

Initiation of the IMAGE1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in Q4 2021

The HIOH pursues an integrative approach to understanding the emergence of new pathogens and developing suitable intervention mechanisms. Ascenion is its technology transfer partner.

Biomax Informatics AG, a well-established start-up from the Helmholtz Zentrum München, has been acquired by Horizonte Venture Management. The proceeds from the sale of Ascenion’s equity will be distributed as research grants via the LifeScience Foundation.

The Berlin start-up uses AI to recognize post-operative complications before they become critical. IBB Ventures and several business angels have invested in the company.

Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius Maximilian University (JMU) in Würzburg have paved the way for a new diagnostic platform that enables the detection of multiple markers in one single test.